Created by an industry veteran with more than 20 years’ experience, Protodigm aims to offer innovation and expertise to pharmaceutical industry clients.
The company reportedly will utilize the investment funding to expand its research platform, and to advance six of its preclinical therapeutic programs.
An expert from synthetic biology tech firm Antheia offers ways to rethink current sourcing and manufacturing strategies to tackle current and future woes.
This month’s roundup of new hires, investment funding, partnerships, and other industry news includes key firms such as Clinical Ink, Medable, CPhI, and Sterling Pharma.
The head of small-molecule business for the pharma solutions specialist talks about obstacles, and how companies can work to clear them for future success.
On May 5, a panel of experienced industry experts will discuss recent developments during Innovations in Drug Delivery, a free one-hour industry webinar.
Published by Tabula Rasa Healthcare, the report looks at the MedWise Risk Score, technology designed to determine ADE risk rising from medication regimens.
An advanced cancer detection platform from C2i Genomics (reportedly capable of spotting miniscule traces of the disease) recently landed $100m in funding.
A leader from the laboratory solutions provider talks about how the virus has created challenges for researchers, and how those obstacles might be cleared.
The science service and technologies firm plans to bring the CRO under its Laboratory Products and Services Segment umbrella after the deal is completed.
The Institute for Clinical and Economic Review will use Aetion observational real-world evidence to evaluate potential drugs from Takeda and CSL Behring.
The collaboration centers on development of precision cancer treatments, through discovery and validation of next-generation DNA damage response targets.
